- Home
- GNTA vs IMAB Comparison
GNTA vs IMAB Comparison
Compare GNTA & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- IMAB
- Stock Information
- Founded
- GNTA 2014
- IMAB 2014
- Country
- GNTA Italy
- IMAB United States
- Employees
- GNTA N/A
- IMAB N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- IMAB Health Care
- Exchange
- GNTA Nasdaq
- IMAB Nasdaq
- Market Cap
- GNTA 96.9M
- IMAB 83.8M
- IPO Year
- GNTA 2021
- IMAB 2020
- Fundamental
- Price
- GNTA $4.69
- IMAB $0.94
- Analyst Decision
- GNTA Strong Buy
- IMAB Strong Buy
- Analyst Count
- GNTA 1
- IMAB 3
- Target Price
- GNTA $25.00
- IMAB $8.00
- AVG Volume (30 Days)
- GNTA 7.4K
- IMAB 380.3K
- Earning Date
- GNTA 01-01-0001
- IMAB 08-28-2024
- Dividend Yield
- GNTA N/A
- IMAB N/A
- EPS Growth
- GNTA N/A
- IMAB N/A
- EPS
- GNTA N/A
- IMAB N/A
- Revenue
- GNTA N/A
- IMAB $3,313,984.00
- Revenue This Year
- GNTA N/A
- IMAB N/A
- Revenue Next Year
- GNTA N/A
- IMAB N/A
- P/E Ratio
- GNTA N/A
- IMAB N/A
- Revenue Growth
- GNTA N/A
- IMAB N/A
- 52 Week Low
- GNTA $2.20
- IMAB $0.90
- 52 Week High
- GNTA $7.28
- IMAB $2.54
- Technical
- Relative Strength Index (RSI)
- GNTA 44.38
- IMAB 34.02
- Support Level
- GNTA $4.44
- IMAB $0.90
- Resistance Level
- GNTA $5.00
- IMAB $1.00
- Average True Range (ATR)
- GNTA 0.44
- IMAB 0.07
- MACD
- GNTA -0.05
- IMAB -0.01
- Stochastic Oscillator
- GNTA 25.40
- IMAB 16.89
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).